Abstract
We conducted a pilot study to assess the effect of atorvastatin on HIV replication. Patients with stable HAART-controlled infection interrupted therapy and were randomly assigned to a control group or to start atorvastatin 40 or 80 mg/day. Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anticholesteremic Agents / administration & dosage*
-
Antiretroviral Therapy, Highly Active*
-
Atorvastatin
-
Cholesterol / blood
-
Dose-Response Relationship, Drug
-
HIV Infections / blood
-
HIV Infections / drug therapy*
-
HIV-1 / physiology*
-
Heptanoic Acids / administration & dosage*
-
Humans
-
Pilot Projects
-
Pyrroles / administration & dosage*
-
RNA, Viral / blood
-
Virus Replication / drug effects*
Substances
-
Anticholesteremic Agents
-
Heptanoic Acids
-
Pyrroles
-
RNA, Viral
-
Cholesterol
-
Atorvastatin